IGM Biosciences, Inc.

Reported hard numbers: Q4 2022 collaboration revenue was $0.4 million and full-year collaboration revenue was $1.1 million. Q4 R&D expense was $45 million and full-year R&D was $179.3 million; Q4 G&A was $11.6 million and full-year G&A was $49.7 million. Q4 net loss was $52.6 million, or $1.19 per share, and full-year net loss was $221.1 million, or $5.32 per share. Cash and investments were $427.2 million at Dec. 31, 2022. For 2023, GAAP operating expenses are expected to be $290 million to $300 million, including about $50 million of non-cash stock-based compensation. Collaboration revenue for 2023 is expected to be about $3 million, and year-end cash and investments are expected to be about $200 million, implying runway into the second half of 2024.

Fred Schwarzer said 2022 was “transformational,” pointing to the Sanofi collaboration, progress with IGM-8444, and a broadening pipeline. He emphasized that the company is now moving quickly into a randomized second-line colorectal cancer trial with IGM-8444 and redirecting imvotamab toward what he sees as larger autoimmune opportunities. His tone was upbeat and strategic, with repeated emphasis on platform validation, potential differentiation, and multiple shots on goal in 2023.

Misbah Tahir highlighted that the company is in a “strong financial position” after receiving the $150 million Sanofi upfront and raising $230 million gross in equity. He detailed 2022 costs and losses, including R&D of $179.3 million, G&A of $49.7 million, and a full-year net loss of $221.1 million, or $5.32 per share. For 2023, he guided to $290 million to $300 million of GAAP operating expenses, roughly $50 million of stock-based comp, about $3 million of collaboration revenue, and year-end cash and investments of approximately $200 million.

Analysts focused heavily on IGM-8444 dose selection, the rationale for adding a 10 mg/kg arm, the biomarker data, and what success would look like in the randomized colorectal cancer study. Management said the 10 mg/kg arm was added because caspase-3 increases looked dose-dependent and the FDA supported formal dose exploration; they also said the trial could potentially support accelerated-approval pathways depending on the strength of the randomized data. On imvotamab, questions centered on the autoimmune pivot and partnership strategy; management said lupus and RA were chosen because CD20 is validated, deep B-cell depletion may matter, and the company may ultimately seek a partner because the autoimmune opportunity is broad and costly to pursue.